Mohammad AskarPublic working copy · medical review pending

Glaucoma treatment in daily life · 156

Glaucoma: make treatment usable in daily life

Before adding treatment, ask how the drops are actually used. Discuss discomfort, technique, access and daily burden without blame.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Simplification, suitable formulations and practical help may improve use. Recheck pressure and progression after a change; fewer bottles or better comfort alone does not prove protection from visual loss.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Understand the practical barrier

Primary open-angle glaucoma is chronic and often symptom-poor for years. Pressure-lowering treatment needs sustained effective delivery; apparent lack of benefit to the patient can undermine adherence even while visual damage progresses silently. 1

Ask about forgetting, doubts, disease understanding, hand dexterity, multiple bottles and dosing frequency. Complex regimens are associated with poorer use in some studies, but frequency alone does not explain every missed dose or prove causation. 1

02Watch the technique and examine the surface

At follow-up, ask what was used and when, whether refills and costs are manageable, and what happens after a missed dose. Watch drop instillation and discuss a product-specific missed-dose plan; an office pressure value alone cannot measure adherence. 1

Burning, itching, tearing, foreign-body sensation and intermittent blur can indicate ocular surface disease. Distinguish dry eye, blepharitis, allergy and medication-associated toxicity; both active ingredients and preservatives can matter, and redness alone does not identify the mechanism. 1 2 3

Apparent resistance can reflect poor technique, short ocular contact, missed refills, temporary stopping or unrecognised steroid exposure. Also review measurement timing, pressure fluctuation, true disease progression and an unsuitable target rather than attributing every high reading to nonadherence. 1

03Simplify safely and select treatment with the patient

Where clinically suitable, fewer daily applications or fixed combinations reduce bottles and preservative contacts. Verify the active drugs, contraindications and dosing: simplifying the container count does not make an unsuitable combination appropriate. 1

Persistent intolerance may justify a suitable preservative-free formulation or an intervention such as selective laser trabeculoplasty or surgery. Decide from target pressure, progression, risks, surface findings and patient preference; neither a formulation change nor intervention guarantees freedom from drops or visual preservation. 1

04Agree support and check whether it worked

Offer written plans, demonstration, suitable drop aids and reminders such as a phone alarm or SMS when acceptable. Older age or motor difficulty may increase support needs, but choose help for the actual barrier and check that the dispenser can be used. 1

Lifestyle discussion can support care but does not replace prescribed therapy or pressure monitoring. Agree changes together and review technique, symptoms, pressure, nerve and visual-field course at the next appropriate visit; earlier assessment is needed for pain, acute loss or progression. 1

In SEE, a nonmasked two-centre randomised trial, 235 adults with self-reported adherence ≤85% received 6 months of coaching plus reminders or written education. Electronic on-time adherence was 77.6% versus 58.0%; the reported difference was 19.7 percentage points (95% CI 13.7–25.6). This tests a combined programme in selected patients, not reminders alone or prevention of visual loss. 8

Electronic monitoring is a proxy for use, and the trial was unmasked with adherence outcomes in 113 and 114 participants. Full attrition, protocol and long-term visual outcomes remain unreviewed. The author disclosed a pending adherence-monitor patent; local feasibility and access must be assessed. 8

What are the main learning points?

Simplification, suitable formulations and practical help may improve use. Recheck pressure and progression after a change; fewer bottles or better comfort alone does not prove protection from visual loss.

When is assessment urgent?

Severe pain, marked redness or sudden visual loss needs urgent assessment. A rapid pressure rise, new field loss or confirmed progression needs prompt specialist review.

References and access status

  1. 1
    Immutable original export; glaucoma adherence lecture

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Hedengran et al. preserved versus alternative/PF glaucoma drops: systematic review 2020

    Historical access reused from review 112: Complete official NCBI abstract read14November2026; full review, individual trials and supplements unread.

  3. 3
    TFOS DEWS II Diagnostic Methodology2017

    Historical access reused from review 112: Selected indexed sections6/8 on tests and homeostasis read14November2026; historical report, not full current DEWSIII appraisal or original unnamed2024 consensus.

  4. 4
    EMA Ikervis product information

    Historical access reused from review 112: Indexed official indication4.1 and selected4.2 plus EPAR summary inspected14November2026; not whole label or all safety sections.

  5. 5
    EMA Roclanda product information

    Historical access reused from review 112: Indexed active-ingredient and hyperaemia4.8 passages inspected14November2026; not full label, and original Rocklander identity unresolved.

  6. 6
    Sarkar et al. Corneal neurotoxicity due to topical BAK2012

    Historical access reused from review 112: Selected indexed primary abstract methods/results and introduction read14November2026; mouse/cell work, not full paper, human nerve-loss estimate or original day3/day6 verification.

  7. 7
    Ishibashi et al. short-term preserved/unpreserved timolol2003

    Historical access reused from review 112: Indexed primary purpose/methods/conclusion read14November2026;20 healthy volunteers; complete results/report unread. No irreversible-denervation inference.

  8. 8
    Newman-Casey et al. SEE randomised clinical trial. JAMA Ophthalmol 2026. PMID 41746659

    Complete indexed abstract and conflict disclosure read 15 November 2026; direct basic PubMed view returned a placeholder. Full report, protocol, supplement, linked commentary and registry not appraised.